News and Trends 6 Apr 2020 UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients …we can prevent or reduce deterioration in Covid-19 patients for which there are currently few treatments available.” Izana’s antibody therapy is a human monoclonal antibody targeting GM-CSF and is in… April 6, 2020 - 2 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
Interview 11 Sep 2017 Meet the CEO of Europe’s Largest & Most Fiercely Independent Biotech …example, a bispecific antibody, we can do this in-house. We’ve been able to create two completely new next-generation antibody technology platforms, DuoBody and HexaBody for bispecific and immune effector function… September 11, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2016 How is European Immuno-Oncology fighting Blood Cancer? …also announced Phase I results for IPH4102, a humanized monoclonal antibody to treat cutaneous T-cell lymphomas (CTCL), a subtype of non-Hodgkin’s lymphoma. Argenx, in the Netherlands, has two antibody… December 6, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 AbbVie acquires LifeArc portfolio company DJS Antibodies AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled… October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Mar 2025 AbbVie and Genmab: Can a legal battle break a billion-dollar bond? …technology related to antibody-drug conjugates (ADCs). Genmab has rejected the claims and said it will defend itself, insisting the dispute will not impact its ongoing collaborations with AbbVie. But it’s… March 25, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2023 Five biotech companies taking Los Angeles by storm …clinical candidate is vudalimab, which is currently in ongoing phase 2 clinical studies in metastatic castration-resistant prostate cancer and gynecologic tumors. The drug is a bispecific antibody that simultaneously targets… September 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2022 Fast Stroke Treatments in the Works with TargED’s €39M Series A …Microlyse is a fusion protein drug combining an antibody fragment with a fragment of a clot-busting enzyme. The antibody part of the drug seeks out a protein target found in… February 22, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Researchers identify possible target for type of sporadic ALS …cells. When a synthetic antibody designed specifically to recognize HERV-K ENV was added as well to those neurons, the toxic effects were reduced. These findings together suggest that the improper… August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2020 Adrenomed’s Antibody Drug Scores Hit in Phase II Septic Shock Trial German biotech Adrenomed reports that its first-in-class antibody drug adrecizumab was well-tolerated by septic shock patients and met its primary goal in a phase II trial. The company says it… February 24, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 13 Jun 2023 Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines …treatment of Alzheimer’s disease In September 2022, the monoclonal antibody lecanemab, which targets a toxic species of Abeta protein, slowed cognitive decline in early Alzheimer’s disease by approximately 30% in… June 13, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2020 Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug …treatment based on antibody-drug conjugate technology from the Dutch company Synaffix. Synaffix develops technology to produce antibody-drug conjugates, commonly known as ADCs, which are antibodies with toxic chemotherapy drugs attached…. January 7, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 25 Oct 2018 Mastering the Competitive World of Immuno-oncology …of the antibody field and started his first company, 4-Antibody, in 2004. Before a successful sale to Agenus in 2014, the company developed therapeutic antibodies for a range of different… October 25, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email